Comparative Study on the Therapeutic Effect of Azacitidine and Decitabine Combined with Venetoclax in Elderly Patients with Acute Myeloid Leukemia
Objective To compare the clinical therapeutic effects of azacitidine and decitabine combined with venetoclax in elderly patients with acute myeloid leukemia.Methods Sixty-two elderly acute myeloid leukemia patients treated at Shangqiu First People's Hospital from February 2021 to August 2023 were selected for the study.According to the different treatment methods,they were divided into a control group(n=31,treated with decitabine combined with venetoclax)and an experimental group(n=31,treated with azacitidine combined with venetoclax).The clinical remission rate,laboratory indicators before and after treatment,immune function indicators,and incidence of adverse reactions were compared between the two groups.Results The clinical remission rate in the experimental group(96.77%)was higher than that in the control group(80.65%),with statistically significant differences(P＜0.05).After treatment,the hemoglobin,white blood cell count,and platelet count indicators in the experimental group were higher than those in the control group,and the bone marrow blast cell indicators were lower than those in the control group,with statistically significant differences(P＜0.05).After treatment,the CD4+and CD4+/CD8+indicators in the experimental group were higher than those in the control group,and the CD8+indicator was lower than that in the control group,with statistically significant differences(P＜0.05).The incidence of hematological toxicity reactions(leukopenia,neutropenia,hemoglobin reduction)and non-hematological toxicity reactions(nausea,vomiting,fever,cough)in the experimental group was lower than that in the control group,with statistically significant differences(P＜0.05).Conclusion Compared with decitabine combined with venetoclax,azacitidine combined with venetoclax has a higher clinical remission rate in the treatment of elderly acute myeloid leukemia,can effectively reduce the impact on the immune and hematological systems,and reduce the incidence of adverse reactions,with higher safety.
万方数据
维普
